FDA Recalls Nationwide Supply of Erythromycin Ophthalmic Ointment for Manufacturing Deviations
Akorn, Inc. is recalling 36,455 cartons of Erythromycin Ophthalmic Ointment USP 0.5% nationwide due to manufacturing process deviations. The company voluntarily initiated this Class II recall.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall based on manufacturing process deviations that could affect product quality and safety. Although no illnesses or injuries have been reported, the lack of compliance with manufacturing standards poses a potential risk of harm to patients using the ophthalmic ointment.
Plain-English summary
Akorn, Inc. is recalling Erythromycin Ophthalmic Ointment USP 0.5% (NDC 17478-070-31) due to current good manufacturing practice (CGMP) deviations. The recall affects 36,455 cartons distributed nationwide in the United States. This is a voluntary Class II recall initiated by the company on October 13, 2022, and classified by the FDA on January 13, 2023. No illnesses or injuries have been reported.
The following lot numbers are affected with their expiration dates: Lot 1B14B (1/31/2023); Lots 1C49A, 1C49B, 1C70A (2/28/2023); Lots 1E09A, 1E34A, 1E34B, 1E09B (4/30/2023); Lots 1F37C, 1F37A, 1F37B (5/31/2023); Lots 1G58A, 1G57B, 1G58B, 1G66B, 1G66A, 1G57A (6/30/2023); Lots 1H77B, 1H80A, 1H80B, 1H77A (7/31/2023); Lot 1J24A (8/31/2023); Lots 1K67B, 1K67A, 1K76A, 1K87B, 1K77A, 1K76B, 1K87A, 1K77B (9/30/2023); Lots 1L90B, 1L90A, 1L92B, 1L92A (10/31/2023); Lots 1M28A, 1M35A, 1M28B (11/30/2023); and Lot 2D20B (3/31/2024).
Healthcare providers and patients should stop using the recalled product. Those with questions or concerns about adverse effects should contact Akorn, Inc. or the FDA. The recall is ongoing.
The recalled product
- Product
- Erythromycin Ophthalmic Ointment USP, 0.5%, Net Weight: 1 g per tube (50 unit-dose tubes per carton), Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. NDC: 17478-070-31
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 1B14B
- EXP 1/31/2023
- 1C49A
- 1C49B
- 1C70A
- EXP 2/28/2023
- 1E09A
- 1E34A
- 1E34B
- 1E09B
- EXP 4/30/2023
- 1F37C
- 1F37A
- 1F37B
- EXP 5/31/2023
- 1G58A
- 1G57B
- 1G58B
- 1G66B
- 1G66A
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27